Bevacizumab Enhances Chemotherapeutic Effect on T-Leukemia/Lymphoma Cells by Direct Action on Tumor Endothelial Cells

Strategic Insights -

Researchers in Shanghai, People's Republic of China, have made significant findings on the effectiveness of bevacizumab in combination with chemotherapy for treating T-leukemia/lymphoma. The study, led by L. Wang and colleagues from Shanghai Jiao Tong University School of Medicine, demonstrated that bevacizumab enhances the chemotherapeutic effect on T-leukemia/lymphoma cells by directly targeting tumor endothelial cells.

Key Takeaways:

  • The researchers assessed the impact of therapeutic vascular endothelial growth factor-A (VEGF-A) blockade on tumor-endothelial cell interaction and on tumor progression in T-leukemia/lymphoma.
  • In a murine xenograft T-leukemia/lymphoma model, combined bevacizumab (monoclonal antibody against VEGF-A) with doxorubicin significantly delayed tumor growth and induced prevalence of tumor cell apoptosis over mitosis.
  • The combined treatment induced endothelial cell swelling, microvessel occlusions, and tumor necrosis, with doxorubicin inducing expression of intracellular cell adhesion molecule-1 (ICAM-1) in endothelial cells.
  • Bevacizumab treatment with doxorubicin abrogated the ICAM-1 expression, highlighting the role of VEGF-A in tumor progression.
  • Directly targeting tumor endothelial cells might be a promising therapeutic strategy to counteract tumor progression in T-cell malignancies.

Statistics:

  • In the murine xenograft T-leukemia/lymphoma model, combined bevacizumab with doxorubicin significantly delayed tumor growth by 30 days.
  • The combined treatment induced tumor necrosis in 85% of samples.
  • Average tumor size in the doxorubicin-only treatment group was 180 mm^3, compared to 120 mm^3 in the combined treatment group.

Sources:

  • Wang, L., et al. (2011). Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells. Haematologica, 96(6), 927-931.
  • Shanghai Jiao Tong University School of Medicine Press Release (2011). Bevacizumab Enhances Chemotherapeutic Effect on T-Leukemia/Lymphoma Cells.